What is MSLN?
MSLN, also known as Mesothelin, is a cell surface glycoprotein encoded by the MSLN gene, anchored to the cell surface by glycosylphosphatidylinositol. This protein was first identified by its reactivity with monoclonal antibody K1. The MSLN protein formation process is as follows: The MSLN gene encodes a proprotein that is proteolytically produced to produce mesothelin and megakaryocyte-potentiating factor (MPF). Mesothelin may play a role in adhesion. Abnormal expression of MSLN plays an important role in tumor cell proliferation, adhesion and drug resistance.
The Structure of MSLN
The MSLN gene was located on chromosome 16 p13.3 with cDNA size of 213 bp. The MSLN gene encodes a precursor protein of 71 KDa. This precursor protein is hydrolyzed into two parts by furin protease: a soluble 31 kDa N-terminal protein called megakaryocyte-potentiating factor (MPF) and a 40 kDa membrane-bound fragment called MSLN.
There are many forms of mesothelin: membrane-bound mesothelin and soluble mesothelin. Soluble mesothelin is a protein of 42-45 kDa, and its NH2-terminal amino acid sequence is identical to membrane-bound mesothelin.
The Expression of MSLN
The name of mesothelin is mainly that the membrane-bound protein encoded by this gene is mainly located on the surface of normal mesothelial cells.
Mesothelin can be expressed in mesothelial cells of the normal pleura, pericardium and peritoneum, and is rarely expressed in normal tissues.
In addition, it is also expressed in a variety of tumor tissues, including mesothelioma, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, esophageal cancer, gastric cancer, cholangiocarcinoma, endometrial cancer, thymic cancer, colon cancer and other tumors.
The Function of MSLN
Mesothelin may play a role in adhesion. With the deepening of research, it has been found to play an important role in the development of various tumors. Aberrant expression of MSLN accelerates cell cycle transition and promotes tumor cell proliferation by regulating cell cycle-associated expression of cyclin E and cyclin-dependent kinase 2 (CDK2). Mesothelin can also increase the tolerance of cancer cells to drugs.
Drug Development Targeting MSLN
Mesothelin is highly expressed in a variety of human malignant cells and is rarely expressed in normal tissues, so mesothelin is expected to be used for tumor-specific therapeutic targets.
More interesting reading>>
Hot Products of MSLN
Recombinant Human Mesothelin(MSLN),partial (Active) (CSB-MP015044HUc9)
Validated Data
Purity determined
by
SDS-PAGE
Greater than 92% as determined by SDS-PAGE.
Excellent Antigen-antibody Binding Bioactivity Validated by Functional ELISA
Immobilized MSLN at 2 μg/ml can bind Anti-MSLN rabbit monoclonal antibody, the EC50 of the MSLN protein is 2.657-3.177 ng/ml.
High Ligand-receptor Binding Bioactivity Validated by Functional ELISA
Immobilized MUC16(CSB-MP704410HU3c7) at 10 μg/ml can bind MSLN, the EC50 is 460.7-662.2 ng/ml.
